2025
Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024
Meah N, Li J, Wall D, York K, Bhoyrul B, Bokhari L, Coulthard L, Asfour L, Abraham L, Asz‐Sigall D, Bergfeld W, Betz R, Blume‐Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Dlova N, Donovan J, Doroshkevich A, Eisman S, Farrant P, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Kossard S, Lee J, Lee W, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Roberts J, Rudnicka L, Saceda‐Corralo D, Shapiro J, Sharma P, Silyuk T, Suchonwanit P, Takwale A, Tosti A, Visser W, Vañó‐Galván S, Vogt A, Wade M, Yip L, Zlotogorski A, Zhou C, Sinclair R. Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024. Journal Of The European Academy Of Dermatology And Venereology 2025 PMID: 40698981, DOI: 10.1111/jdv.20833.Peer-Reviewed Original ResearchFrontal fibrosing alopeciaPrognostic indicatorIncidence of frontal fibrosing alopeciaOptimal treatment algorithmEvidence-based treatment recommendationsThree-round Delphi processInternational consensus statementSystemic therapyTreatment algorithmTreatment modalitiesPhysical therapyTreatment recommendationsConsensus statementDelphi processRobust researchExpert consensusConsensus thresholdDisease monitoringConsensus agreementTherapyMultiple sclerosis: 2024 update
Klotz L, Saraste M, Airas L, Kuhlmann T. Multiple sclerosis: 2024 update. Free Neuropathology 2025, 6: 14. PMID: 40636815, PMCID: PMC12238822, DOI: 10.17879/freeneuropathology-2025-6762.Peer-Reviewed Original ResearchEpstein-Barr virusMultiple sclerosisCAR-T cell therapyT-cell therapyComplex immune-mediated diseaseImmune-mediated diseasesMS disease progressionAdvanced imaging techniquesTreatment strategiesFocal inflammationDisease progressionMS progressionNeurological disabilityPersonalized treatmentDiagnostic criteriaDiagnostic specificityTherapeutic developmentDisease monitoringMRI markersCriteria revisionImaging techniquesBiomarkersGenetic discoveriesDiseaseFluid biomarkers
2019
PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES
Carniti C, Biancon G, Banfi S, Vella C, Magni M, Pennisi M, Anna D, Guidetti A, Corradini P. PS1313 FEASIBILITY AND PRELIMINARY RESULTS OF A PROSPECTIVE EVALUATION OF RESIDUAL DISEASE IN DIFFUSE LARGE B‐CELL LYMPHOMAS USING DEEP SEQUENCING OF CELL FREE DNA AND DNA FROM FORMALIN FIXED BIOPSIES. HemaSphere 2019, 3: 599-600. DOI: 10.1097/01.hs9.0000563532.69483.ec.Peer-Reviewed Original ResearchCell-free DNADLBCL patientsIgH gene rearrangementTumor burdenResidual diseaseIgH rearrangementsGene rearrangementsDiffuse large B-cell lymphoma patientsLarge B-cell lymphoma patientsB-cell lymphoma patientsDiffuse large B-cell lymphomaLarge B-cell lymphomaPossible disease progressionPossible residual diseaseR-CHOP therapyBaseline plasma samplesLymph node biopsyDisease monitoringImmunoglobulin heavy chain gene rearrangementMultiple myeloma patientsNon-invasive disease monitoringCell lymphoma patientsNumber of patientsFFPE samplesPET-CT scan
2016
Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements
Gimondi S, Biancon G, Vendramin A, Zaninelli S, Rizzitano S, Malan S, Bermema A, Montefusco V, Carniti C, Corradini P. Disease Monitoring in Multiple Myeloma Patients Using Liquid Biopsy and Next Generation Sequencing of IGH Gene Rearrangements. Blood 2016, 128: 4430. DOI: 10.1182/blood.v128.22.4430.4430.Peer-Reviewed Original ResearchCell-free tumor DNAMinimal residual diseaseIgH gene rearrangementMultiple myeloma patientsTime pointsTumor burdenMyeloma patientsGene rearrangementsLiquid biopsyPlasma samplesInternational Myeloma Working Group Uniform Response CriteriaTime of CRSequential plasma samplesBone marrow infiltrationDisease monitoringResidual tumor burdenNon-invasive strategyImmunoglobulin gene rearrangementsMM ptsPresence of subclonesSpecific clonotypesProgressive diseaseMarrow infiltrationMRD monitoringResidual diseaseBayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease
Zhang X, Mormino E, Sun N, Sperling R, Sabuncu M, Yeo B, Weiner M, Aisen P, Weiner M, Aisen P, Petersen R, Jack C, Jagust W, Trojanowki J, Toga A, Beckett L, Green R, Saykin A, Morris J, Shaw L, Khachaturian Z, Sorensen G, Carrillo M, Kuller L, Raichle M, Paul S, Davies P, Fillit H, Hefti F, Holtzman D, Mesulam M, Potter W, Snyder P, Schwartz A, Green R, Montine T, Petersen R, Aisen P, Thomas R, Donohue M, Walter S, Gessert D, Sather T, Jiminez G, Balasubramanian A, Mason J, Sim I, Beckett L, Harvey D, Donohue M, Jack C, Bernstein M, Fox N, Thompson P, Schuff N, DeCArli C, Borowski D, Gunter J, Senjem M, Vemuri P, Jones D, Kantarci K, Ward C, Jagust W, Koeppe R, Foster N, Reiman E, Chen K, Mathis C, Landau S, Morris J, Cairns N, Franklin E, Taylor-Reinwald L, Shaw L, Trojanowki J, Lee V, Korecka M, Figurski M, Toga A, Crawford K, Neu S, Saykin A, Foroud T, Potkin S, Shen L, Faber K, Kim S, Nho K, Weiner M, Thal L, Khachaturian Z, Thal L, Buckholtz N, Weiner M, Snyder P, Potter W, Paul S, Albert M, Frank R, Khachaturian Z, Hsiao J, Kaye J, Quinn J, Silbert L, Lind B, Carter R, Dolen S, Schneider L, Pawluczyk S, Becerra M, Teodoro L, Spann B, Brewer J, Vanderswag H, Fleisher A, Heidebrink J, Lord J, Petersen R, Mason S, Albers C, Knopman D, Johnson K, Doody R, Villanueva-Meyer J, Pavlik V, Shibley V, Chowdhury M, Rountree S, Dang M, Stern Y, Honig L, Bell K, Ances B, Morris J, Carroll M, Creech M, Franklin E, Mintun M, Schneider S, Oliver A, Marson D, Geldmacher D, Love M, Griffith R, Clark D, Brockington J, Roberson E, Grossman H, Mitsis E, Shah R, deToledo-Morrell L, Duara R, Greig-Custo M, Barker W, Albert M, Onyike C, D’Agostino D, Kielb S, Sadowski M, Sheikh M, Ulysse A, Gaikwad M, Doraiswamy P, Petrella J, Borges-Neto S, Wong T, Coleman E, Arnold S, Karlawish J, Wolk D, Clark C, Smith C, Jicha G, Hardy P, Sinha P, Oates E, Conrad G, Lopez O, Oakley M, Simpson D, Porsteinsson A, Goldstein B, Martin K, Makino K, Ismail M, Brand C, Potkin S, Preda A, Nguyen D, Womack K, Mathews D, Quiceno M, Levey A, Lah J, Cellar J, Burns J, Swerdlow R, Brooks W, Apostolova L, Tingus K, Woo E, Silverman D, Lu P, Bartzokis G, Graff-Radford N, Parfitt F, Poki-Walker K, Farlow M, Hake A, Matthews B, Brosch J, Herring S, van Dyck C, Carson R, MacAvoy M, Varma P, Chertkow H, Bergman H, Hosein C, Black S, Stefanovic B, Caldwell C, Hsiung G, Mudge B, Sossi V, Feldman H, Assaly M, Finger E, Pasternack S, Rachisky I, Trost D, Kertesz A, Bernick C, Munic D, Mesulam M, Rogalski E, Lipowski K, Weintraub S, Bonakdarpour B, Kerwin D, Wu C, Johnson N, Sadowsky C, Villena T, Turner R, Johnson K, Reynolds B, Sperling R, Johnson K, Marshall G, Yesavage J, Taylor J, Lane B, Rosen A, Tinklenberg J, Sabbagh M, Belden C, Jacobson S, Sirrel S, Kowall N, Killiany R, Budson A, Norbash A, Johnson P, Obisesan T, Wolday S, Allard J, Lerner A, Ogrocki P, Tatsuoka C, Fatica P, Fletcher E, Maillard P, Olichney J, DeCarli C, Carmichael O, Kittur S, Borrie M, Lee T, Bartha R, Johnson S, Asthana S, Carlsson C, Potkin S, Preda A, Nguyen D, Tariot P, Burke A, Milliken A, Trncic N, Fleisher A, Reeder S, Bates V, Capote H, Rainka M, Scharre D, Kataki M, Kelley B, Zimmerman E, Celmins D, Brown A, Pearlson G, Blank K, Anderson K, Flashman L, Seltzer M, Hynes M, Santulli R, Sink K, Gordineer L, Williamson J, Garg P, Watkins F, Ott B, Tremont G, Daiello L, Salloway S, Malloy P, Correia S, Rosen H, Miller B, Perry D, Mintzer J, Spicer K, Bachman D, Finger E, Pasternak S, Rachinsky I, Rogers J, Kertesz A, Drost D, Pomara N, Hernando R, Sarrael A, Schultz S, Smith K, Koleva H, Nam K, Shim H, Relkin N, Chiang G, Lin M, Ravdin L, Smith A, Raj B, Fargher K. Bayesian model reveals latent atrophy factors with dissociable cognitive trajectories in Alzheimer’s disease. Proceedings Of The National Academy Of Sciences Of The United States Of America 2016, 113: e6535-e6544. PMID: 27702899, PMCID: PMC5081632, DOI: 10.1073/pnas.1611073113.Peer-Reviewed Original ResearchConceptsAtrophy factorAtrophy patternsCortical factorsDementia patientsAlzheimer's disease dementia patientsDistinct atrophy patternsStrong associationEntire clinical spectrumAD dementia patientsExecutive function declineExecutive functionSubcortical factorsFunction declineClinical spectrumEarly ADAlzheimer's diseaseStructural MRIDisease monitoringNormal participantsMemory declineMCI participantsDifferent cognitive domainsPatientsFactor compositionCognitive trajectoriesProstate Cancer, Version 1.2016.
Mohler J, Armstrong A, Bahnson R, D'Amico A, Davis B, Eastham J, Enke C, Farrington T, Higano C, Horwitz E, Hurwitz M, Kane C, Kawachi M, Kuettel M, Lee R, Meeks J, Penson D, Plimack E, Pow-Sang J, Raben D, Richey S, Roach M, Rosenfeld S, Schaeffer E, Skolarus T, Small E, Sonpavde G, Srinivas S, Strope S, Tward J, Shead D, Freedman-Cass D. Prostate Cancer, Version 1.2016. Journal Of The National Comprehensive Cancer Network 2016, 14: 19-30. PMID: 26733552, DOI: 10.6004/jnccn.2016.0004.Peer-Reviewed Original ResearchConceptsProstate cancerMetastatic castration-recurrent prostate cancerCastration-recurrent prostate cancerTreatment of recurrent diseaseDiagnosis of prostate cancerRisk stratification methodsTreatment of menMetastatic diseaseRecurrent diseaseSystemic therapyNCCN guidelinesHigh riskDiseaseDisease monitoringCancerNCCNManagement optionsStratification methodTreatmentRiskOptionsProstateTherapyGuidelinesDiagnosis
2015
Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma
de la Fuente MI, Young RJ, Rubel J, Rosenblum M, Tisnado J, Briggs S, Arevalo-Perez J, Cross JR, Campos C, Straley K, Zhu D, Dong C, Thomas A, Omuro AA, Nolan CP, Pentsova E, Kaley TJ, Oh JH, Noeske R, Maher E, Choi C, Gutin PH, Holodny AI, Yen K, DeAngelis LM, Mellinghoff IK, Thakur SB. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma. Neuro-Oncology 2015, 18: 283-290. PMID: 26691210, PMCID: PMC4724186, DOI: 10.1093/neuonc/nov307.Peer-Reviewed Original ResearchConceptsTumor volumeDisease monitoringIsocitrate dehydrogenase (IDH) mutant gliomasProton magnetic resonance spectroscopyConsecutive glioma patientsMR imaging protocolMagnetic resonance spectroscopyCytoreductive therapyTumor levelsLarge tumorsTumor gradeSmall tumorsGlioma patientsGlioma imagingGlioma therapyClinical practiceClinical implicationsRoutine MRTumor cellularityTumor cellsIDH-mutant gliomasGliomasMetabolite RImaging protocolMitotic index
2008
Management of non‐neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring
Cox TM, Aerts JM, Belmatoug N, Cappellini MD, vom Dahl S, Goldblatt J, Grabowski GA, Hollak CE, Hwu P, Maas M, Martins AM, Mistry PK, Pastores GM, Tylki‐Szymanska A, Yee J, Weinreb N. Management of non‐neuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. Journal Of Inherited Metabolic Disease 2008, 31: 319-336. PMID: 18509745, DOI: 10.1007/s10545-008-0779-z.Peer-Reviewed Original ResearchConceptsNon-neuronopathic Gaucher diseaseLong-term disease outcomesGaucher diseaseBone marrow infiltrationManagement of pregnancyAchievable treatment goalsUse of biomarkersBisphosphonate therapyBisphosphonate treatmentMarrow infiltrationTherapeutic eraDisease management approachDisease outcomeTreatment goalsBone diseaseContemporary clinical researchEnzyme replacementBiochemical markersDisease severityClinical researchDiseaseDisease monitoringSplenectomyAppropriate usePregnancy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply